PRODUCT INFORMATION

Fosinopril-d_7 (sodium salt)

Item No. 31917

CAS Registry No.: 1217819-83-4
Formal Name: (2S,4S)-4-cyclohexyl-1-(2-((R)-((S)-2-methyl-1-(propionyloxy)propoxy)(4-(phenyl-d_5)butyl-4,4-d_2)phosphoryl)acetyl)pyrrolidine-2-carboxylate, monosodium salt
MF: $C_{30}H_{38}D_7NO_7P \bullet Na$
FW: 592.7
Chemical Purity: ≥98% (Fosinopril)
Deuterium Incorporation: ≥99% deuterated forms (d_1-d_7); ≤1% d_0
Supplied as: A solid
Storage: -20°C
Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Fosinopril-d_7 (sodium salt) is intended for use as an internal standard for the quantification of fosinopril (Item No. 21899) by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated *versus* unlabeled).

Fosinopril-d_7 (sodium salt) is supplied as a solid. A stock solution may be made by dissolving the fosinopril-d_7 (sodium salt) in the solvent of choice, which should be purged with an inert gas. Fosinopril-d_7 (sodium salt) is soluble in a 1:1 solution of acetonitrile:methanol. Fosinopril-d_7 (sodium salt) is also soluble in DMSO.

Description

Fosinopril is a prodrug form of the angiotensin-converting enzyme (ACE) inhibitor fosinoprilat.[1] Oral administration of fosinopril inhibits angiotensin I-induced pressor responses in normotensive rats, dogs, and monkeys when administered at doses of 15, 15, and 10 µmol/kg, respectively. Fosinopril (2.5 mg/kg) reduces fractional shortening and decreases left ventricular size in a porcine model of congestive heart failure.[2] Formulations containing fosinopril have been used in the treatment of hypertension and congestive heart failure.

References

1. DeForrest, J.M., Waldron, T.L., Harvey, C., *et al.* Fosinopril, a phosphinic acid inhibitor of angiotensin I converting enzyme: *In vitro* and preclinical *in vivo* pharmacology. *J. Cardiovasc. Pharmacol.* **14(5)**, 730-736 (1989).
2. McElmurray, J.H., III, Mukherjee, R., New, R.B., *et al.* Angiotensin-converting enzyme and matrix metalloproteinase inhibition with developing heart failure: Comparative effects on left ventricular function and geometry. *J. Pharmacol. Exp. Ther.* **291(2)**, 799-811 (1999).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM